Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024
29 Mai 2024 - 1:30PM
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its
participation in the Jefferies Global Healthcare Conference. Jeff
Wade, Lexicon’s president and chief financial officer and Craig
Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief
medical officer, will participate in a moderated discussion on
Wednesday, June 5, 2024, at 3:00 pm ET.
A simultaneous webcast will be available in the
“Events” section of the Lexicon website at
www.lexpharma.com/events, and a recording of the webcast will be
available for two weeks following the original on-demand date.
About Lexicon PharmaceuticalsLexicon is a
biopharmaceutical company with a mission of pioneering medicines
that transform patients’ lives. Through the Genome5000™ program,
Lexicon’s unique genomics target discovery platform, Lexicon
scientists studied the role and function of nearly 5,000 genes and
identified more than 100 protein targets with significant
therapeutic potential in a range of diseases. Through the precise
targeting of these proteins, Lexicon is pioneering the discovery
and development of innovative medicines to treat disease safely and
effectively. Lexicon has commercially launched one of these
medicines, INPEFA® (sotagliflozin) in the United States, and has a
pipeline of other promising drug candidates in discovery and
clinical and preclinical development in neuropathic pain, diabetes
and metabolism and other indications. For additional information,
please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking
statements,” including statements relating to Lexicon’s financial
position and long-term outlook on its business, growth and future
operating results, discovery, development and commercialization of
products, strategic alliances and intellectual property, as well as
other matters that are not historical facts or information. All
forward-looking statements are based on management’s current
assumptions and expectations and involve risks, uncertainties and
other important factors, specifically including Lexicon’s ability
to meet its capital requirements, successfully commercialize INPEFA
in heart failure, conduct preclinical and clinical development and
obtain necessary regulatory approvals of sotagliflozin (in other
indications), LX9211, LX9851 and its other drug candidates on its
anticipated timelines, achieve its operational objectives, obtain
patent protection for its discoveries and establish strategic
alliances, as well as additional factors relating to manufacturing,
intellectual property rights, and the therapeutic or commercial
value of its products and drug candidates. Any of these risks,
uncertainties and other factors may cause Lexicon’s actual results
to be materially different from any future results expressed or
implied by such forward-looking statements. Information identifying
such important factors is contained under “Risk Factors” in
Lexicon’s annual report on Form 10-K for the year ended December
31, 2023 and other subsequent disclosure documents filed with the
Securities and Exchange Commission. Lexicon undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or
otherwise.
For Investor Inquiries:
Lisa DeFrancesco Lexicon Pharmaceuticals,
Inc.lexinvest@lexpharma.com
For Media Inquiries:
Alina CocuzzaLexicon Pharmaceuticals,
Inc.acocuzza@lexpharma.com
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024